Impact of rosuvastatin on pulse-wave velocity in men with HIV at moderate cardiovascular risk
- Details
- Publication Year 2024-09-01,Volume 38,Issue #11,Page 1722-1724
- Journal Title
- AIDS
- Publication Type
- Research article
- Abstract
- This single-centre substudy of a double-blind, randomized, placebo-controlled trial aimed to determine the effect of 96 weeks of rosuvastatin on pulse wave velocity (PWV) in men (n = 55, 54 years) with HIV at moderate cardiovascular risk (Framingham risk score 10-15%). PWV increased in both rosuvastatin [0.54 m/s standard error of difference (SED) 0.26] and placebo [0.50 m/s (SED 0.26), P = 0.896] arms, leading to no difference in PWV at week 96 [rosuvastatin 9.40 m/s (SE 0.31); placebo 9.21 m/s (SE0.31), P = 0.676].
- Publisher
- Wolters Kluwer
- Keywords
- Humans; *Rosuvastatin Calcium/therapeutic use/administration & dosage; Male; *HIV Infections/drug therapy/complications; Middle Aged; Double-Blind Method; *Pulse Wave Analysis; *Cardiovascular Diseases; Placebos/administration & dosage; Adult; Sulfonamides/therapeutic use/pharmacology; Treatment Outcome; Pyrimidines; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use; Fluorobenzenes/therapeutic use
- Department(s)
- Infectious Diseases
- Publisher's Version
- https://doi.org/10.1097/qad.0000000000003930
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-09-03 07:46:58
Last Modified: 2024-09-03 07:49:20